Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

BATs in Patients With Breast Cancer and Leptomeningeal Metastases

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03661424
Recruitment Status : Recruiting
First Posted : September 7, 2018
Last Update Posted : April 16, 2019
Sponsor:
Information provided by (Responsible Party):
Camilo E. Fadul, MD, University of Virginia

Brief Summary:

This study uses bi-specific antibody (HER2Bi) armed activated T-cells (HER2 BATs) to target breast cancer cells that have metastasized to the membranes surrounding the brain and spinal cord. This is known as leptomeningeal metastases. Two doses will be evaluated in order to determine a safe dose.

Study treatment includes a test dose of HER2 BATs followed by 8 weekly infusions of HER2 BATs at the assigned dose level. Before, during and after study treatment, participants will be monitored objectively by brain MRIs and clinically through physical and neurological exams, and blood and cerebrospinal fluid will be collected to evaluate immune responses.


Condition or disease Intervention/treatment Phase
Breast Cancer Female Leptomeningeal Metastases Drug: HER2 BATs Phase 1

Detailed Description:
Once subjects are determined eligible, blood will be collected in order to make the HER2 BATs. For HER2 BATs, the white blood cells, specifically T cells, are then mixed with two proteins - OKT3 and IL-2 -- which activates the cells to multiply. After approximately 14 days in culture, the activated T cells are coated with OKT3 and trastuzumab/Herceptin (HER2Bi), and washed to remove excess Herceptin in order to produce bispecific antibody armed T cells (BATs). Cells are then frozen and stored until scheduled to be infused. Up to 2 weeks following blood collection, participants will undergo surgery to place the catheter/reservoir into the lateral ventricle of the brain to allow intraventricular administration of HER2 BATs and a chemotherapy agent methotrexate. A few weeks later, participants will receive the intraventricular methotrexate in order to control disease while the BATs product is being manufactured. About 4-5 weeks following the initial blood collection and at least 7 days after receiving methotrexate, study treatment will begin with a test dose of HER2 BATs. If this dose is well tolerated by the participant, she will then receive 8 weekly doses of HER2 BATs at the assigned dose level.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Anti-CD3 x Anti-Her2/Neu (Her2Bi) Armed Activated T Cells (ATC) in Patients With Breast Cancer Leptomeningeal Metastases
Actual Study Start Date : February 26, 2019
Estimated Primary Completion Date : April 28, 2021
Estimated Study Completion Date : August 30, 2023

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Breast Cancer

Arm Intervention/treatment
Experimental: Test dose then 8 doses HER2 Bi-armed activated T-cells (BATs)
Approximately 4 weeks following registration and blood collection, participants are given a test dose of HER2 BATs followed by 8 weekly infusions. Infusions are given intraventricularly.
Drug: HER2 BATs
A test dose (1 million cells) of HER2 BATs (at one of the two dose levels: 5 million cells or 10 million cells per infusion) followed by 8 weekly infusions of Her2 BATs delivered into the ventricle of the brain. Infusions are delivered weekly over 8 weeks with brain MRIs prior to first infusion and following the eighth infusion. Blood will be drawn for immune evaluation before during and after study treatment.




Primary Outcome Measures :
  1. Types of adverse events (AEs) [ Time Frame: For each participant, AEs will be collected from the time of the first protocol-related procedure through 30 days following last infusion of BATs. SAEs considered related to study treatment will also be collected following this period. ]
    Types of any adverse events or abnormalities of laboratory tests

  2. Frequency of adverse events (AEs) [ Time Frame: For each participant, AEs will be collected from the time of the first protocol-related procedure through 30 days following last infusion of BATs. SAEs considered related to study treatment will also be collected following this period. ]
    Frequency of any adverse events or abnormalities of laboratory tests

  3. Severity of adverse events (AEs) [ Time Frame: For each participant, AEs will be collected from the time of the first protocol-related procedure through 30 days following last infusion of BATs. SAEs considered related to study treatment will also be collected following this period. ]
    Severity of any adverse events or abnormalities of laboratory tests

  4. Timing of onset of adverse events [ Time Frame: For each participant, AEs will be collected from the time of the first protocol-related procedure through 30 days following last infusion of BATs. SAEs considered related to study treatment will also be collected following this period. ]
    Timing of onset of any adverse events or abnormalities of laboratory tests

  5. Duration of adverse events [ Time Frame: For each participant, AEs will be collected from the time of the first protocol-related procedure through 30 days following last infusion of BATs. SAEs considered related to study treatment will also be collected following this period. ]
    Duration of any adverse events or abnormalities of laboratory tests

  6. Relationship to study therapy of any adverse events or abnormalities of laboratory tests as determined by CTCAE v5.0 will be assessed based on protocol-defined relationships of definitely, probably, possibly, unlikely and unrelated to study therapy. [ Time Frame: For each participant, AEs will be collected from the time of the first protocol-related procedure through 30 days following last infusion of BATs. SAEs considered related to study treatment will also be collected following this period. ]
    Relationship to study therapy of any adverse events or abnormalities of laboratory tests

  7. Number of participants achieving at least 80% of the planned HER2 BATs dose. [ Time Frame: An average of 4 weeks following blood draw to collect cells for HER2 BATs ]
    If at least 80% of the planned dose of cells cannot be produced for 3 consecutive participants at a designated dose level, that dose level will be considered not feasible.


Secondary Outcome Measures :
  1. Immune shift: in vitro cytotoxicity assays and/or IFN-y EliSpots against breast cancer cell lines [ Time Frame: Blood for immune analysis collected prior to, during and following study treatment (tx) (up to 6 months following study tx). ]
    Immune shift induced by Her2 BATs as detected by in vitro cytotoxicity assays and/or IFN-γ EliSpots against breast cancer cell lines

  2. Immune shift: Phenotyping of activating and regulatory immune cells [ Time Frame: Blood for immune analysis collected prior to, during and following study treatment (tx) (up to 6 months following study tx). ]
    Immune shift induced by Her2 BATs as detected by phenotyping of activating and regulatory immune cells

  3. Immune shift: Measurement of cytokine patterns [ Time Frame: Blood for immune analysis collected prior to, during and following study treatment (tx) (up to 6 months following study tx). ]
    Immune shift induced by Her2 BATs as detected by measurement of cytokine patterns

  4. Immune shift: Determination of anti-Her2 antibodies [ Time Frame: Blood for immune analysis collected prior to, during and following study treatment (tx) (up to 6 months following study tx). ]
    Immune shift induced by Her2 BATs as detected by determination of anti-Her2 antibodies

  5. Correlation of clinical and immune response characteristics to progression-free survival [ Time Frame: Blood collected prior to, during and following study treatment (tx) (up to 6 months following study tx). Clinical characteristics and imaging prior to and after study tx through 1st progression ]
    Correlation individually and by heatmap analysis of imaging, pathology, clinical, and immune response characteristics to progression free survival (PFS)

  6. Correlation of clinical and immune response characteristics to overall survival [ Time Frame: Blood for immune analysis collected prior to, during and after study treatment (tx) (up to 6 months following study tx). Clinical characteristics and imaging prior to and after study tx through 1st progression ]
    Correlation individually and by heatmap analysis of imaging, pathology, clinical, and immune response characteristics to overall survival (OS).

  7. Objective response rate (ORR) [ Time Frame: Assessed on MRI studies done 9 weeks after first BATs infusion ]
    Proportion of participants with complete or partial response according to brain and spine MRI

  8. Progression-free survival (PFS) [ Time Frame: From date of first BATs infusion (approximately 4 weeks following eligibility confirmation) until the date of confirmed progression, assessed up to 28 months ]
    Length of time from study participation initiation through disease progression for each participant

  9. Overall survival (OS) [ Time Frame: Through each participant's death or for 2 years following study treatment ]
    Length of time from study participation initiation through death or for 2 years following study treatment for each participant

  10. MD Anderson Symptom Inventory for Spinal Tumors (MDASI - SP) [ Time Frame: Prior to test dose of study treatment, prior to the 5th and 8th weekly infusions, and 30 days following last infusion ]
    The MDASI- SP is a 24 item questionnaire that focuses on symptoms related to spinal tumors. For each potential symptom, there is an eleven-point scale where 0 is "Not Present" and 10 is "As Bad As You Can Imagine" so the minimum score would be 0 and the maximum score would be 240. For a subset of questions, the scale measures how much the symptoms interfered with other parts of life and the scale ranges from symptoms that "Did Not Interfere" (0) to those that "Interfered Completely" (10). Lower scores indicate fewer/less severe/less interfering symptoms and higher scores indicate more/more severe/more interfering symptoms.

  11. MD Anderson Symptom Inventory for Brain Tumors (MDASI- BT) [ Time Frame: Prior to test dose of study treatment, prior to the 5th and 8th weekly infusions, and 30 days following last infusion ]
    The MDASI- BT is a 28 item questionnaire that focuses on symptoms related to brain tumors. For each potential symptom, there is an eleven-point scale where 0 is "Not Present" and 10 is "As Bad As You Can Imagine" so the minimum score would be 0 and the maximum score would be 280. For a subset of questions, the scale measures how much the symptoms interfered with other parts of life and the scale ranges from symptoms that "Did Not Interfere" (0) to those that "Interfered Completely" (10). Lower scores indicate fewer/less severe/less interfering symptoms and higher scores indicate more/more severe/more interfering symptoms.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Be willing and able to provide written informed consent for the trial.
  2. Participants must be female.
  3. Histologically confirmed breast cancer (any Her2, estrogen receptor (ER), or progesterone receptor (PR) expression) with leptomeningeal metastasis (LM) as determined by imaging and/or cerebrospinal fluid (CSF) cytology.
  4. 18 years of age or older.
  5. Women of reproductive potential must agree to use an effective method of contraception during therapy. Effective methods include intrauterine device (IUD), vasectomy of the male partner, diaphragm with spermicide, cervical cap with spermicide, contraceptive sponge, male or female condom, or hormonal contraceptive.
  6. Karnofsky Performance Status (KPS) of ≥60.
  7. Eligible for intraventricular (IVENT) catheter/reservoir placement as determined by neurosurgery.
  8. Demonstrate adequate organ function as defined below. All screening labs should be performed within 10 days of confirmation of eligibility.

Absolute lymphocyte count ≥ 500/mm3 Absolute neutrophil count ≥ 1000/mcL Platelets ≥ 100,000 / mnL Hemoglobin ≥ 8 g/dL BUN ≤ 1.5 x upper limit of normal (ULN) Serum creatinine within the normal limits OR measured or calculated creatinine clearance ≥ 60 mL/min 1.73m2 Serum total bilirubin ≤ 2 x ULN OR AST (SGOT) and ALT (SGPT) ≤ 5 x ULN Albumin ≥ 2.5 mg/dL

Exclusion Criteria:

  1. Current severe increased intracranial pressure with clinical or imaging findings suggestive of herniation, status epilepticus, or other serious complications requiring emergency or urgent intervention.
  2. Patients who cannot have MRI studies for any reason (intolerance, medical contraindication, etc.).
  3. Patients with a history of another malignancy within 1 year of study enrollment with the following exceptions: patients with history of ductal carcinoma in situ (DCIS), squamous cell skin cancers, or other in situ carcinomas are not excluded.
  4. Patients with unresolved autoimmune toxicity.
  5. Patients with a known disorder that increases the risk of bleeding (e.g., Hemophilia, von Willebrands disease, or clinically significant clotting factor deficiency).
  6. Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  7. Administration of any investigational agents, immunomodulating agents, radiation therapy or chemotherapy for MBC within the 7 days before the 80 mL blood draw to collect cells for study treatment.
  8. Has Human Immunodeficiency Virus (HIV) (HIV 1/2 antibodies) or known active Hepatitis B (e.g. HBsAg reactive) or Hepatitis C (e.g., HCV RNA [qualitative] is detected).
  9. Pregnancy or lactation at the time of registration.
  10. Psychiatric or addictive disorders or other conditions that in the opinion of the investigator would preclude the patient from complying with the study protocol.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03661424


Contacts
Layout table for location contacts
Contact: Jungeun Kim, PhD 434-982-3365 jk9te@hscmail.mcc.virginia.edu
Contact: Lawrence Lum, MD, DSc 434-243-1375 lgl4f@virginia.edu

Locations
Layout table for location information
United States, Virginia
University of Virginia Recruiting
Charlottesville, Virginia, United States, 22908
Contact: Jungeun Kim, PhD    434-982-3365    jk9te@hscmail.mcc.virginia.edu   
Principal Investigator: Camilo Fadul, MD         
Sponsors and Collaborators
University of Virginia
Investigators
Layout table for investigator information
Principal Investigator: Camilo Fadul, MD University of Virginia

Publications:
Layout table for additonal information
Responsible Party: Camilo E. Fadul, MD, Professor, University of Virginia
ClinicalTrials.gov Identifier: NCT03661424     History of Changes
Other Study ID Numbers: 20805
First Posted: September 7, 2018    Key Record Dates
Last Update Posted: April 16, 2019
Last Verified: April 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Camilo E. Fadul, MD, University of Virginia:
Metastatic Breast Cancer
Adoptive Cell Therapy
Armed Activated T-cells
Bispecific Antibodies
Immunotherapy
Additional relevant MeSH terms:
Layout table for MeSH terms
Breast Neoplasms
Neoplasm Metastasis
Meningeal Carcinomatosis
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Neoplastic Processes
Pathologic Processes
Meningeal Neoplasms
Central Nervous System Neoplasms
Nervous System Neoplasms
Nervous System Diseases